Format

Send to

Choose Destination
Can J Physiol Pharmacol. 2017 Apr;95(4):311-327. doi: 10.1139/cjpp-2016-0346. Epub 2017 Mar 6.

Cannabinoid signaling in health and disease.

Lu Y1,2, Anderson HD1,2,3.

Author information

1
a College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Avenue, Winnipeg, MB R3E 0T5, Canada.
2
b Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Hospital Research Centre, 351 Taché Avenue, Winnipeg, MB R2H 2A6, Canada.
3
c Department of Pharmacology and Therapeutics, Max Rady College of Medicine, University of Manitoba, 753 McDermot Avenue, Winnipeg, MB R3E 0T6, Canada.

Abstract

Cannabis sativa has long been used for medicinal purposes. To improve safety and efficacy, compounds from C. sativa were purified or synthesized and named under an umbrella group as cannabinoids. Currently, several cannabinoids may be prescribed in Canada for a variety of indications such as nausea and pain. More recently, an increasing number of reports suggest other salutary effects associated with endogenous cannabinoid signaling including cardioprotection. The therapeutic potential of cannabinoids is therefore extended; however, evidence is limited and mechanisms remain unclear. In addition, the use of cannabinoids clinically has been hindered due to pronounced psychoactive side effects. This review provides an overview on the endocannabinoid system, including known physiological roles, and conditions in which cannabinoid receptor signaling has been implicated.

KEYWORDS:

2-arachidonoylglycerol; 2-arachidonoylglycérol; FAAH; MAGL; anandamide; cannabinoid receptor; endocannabinoid; endocannabinoïde; récepteur des cannabinoïdes

PMID:
28263083
DOI:
10.1139/cjpp-2016-0346
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center